<?xml version="1.0"?>
<rss version="2.0">
<channel>
<title>The Doctors Lounge - Oncology</title>
<link>http://www.doctorslounge.com/rss/oncology.xml</link>
<description>The latest oncology news from the The Doctors Lounge - Oncology.</description>
<language>en-us</language>
<copyright>Copyright © 2001-2006 The Doctors Lounge. All rights reserved.</copyright>
<image>
<url>http://www.doctorslounge.com/rss/rss.gif</url>
<title>The Doctors Lounge - RSS</title>
<link>http://www.doctorslounge.com/rss/index.htm</link>
<width>120</width>
<height>60</height>
</image>
<item>
<title>Tamoxifen for breast cancer prevention of little benefit</title>
<link>http://www.doctorslounge.com/oncology/articles/breast/tamoxifen_prevention/index.htm</link>
<description>Only women at very high risk for breast cancer experience a benefit according to a study published in the journal Cancer.</description>
</item>
<item>
<title>Breakthrough test clearly distinguishes Burkitt lymphoma from DLBCL</title>
<link>http://www.doctorslounge.com/oncology/articles/lymphoma/burkitt_gene_signature/index.htm</link>
<description>A gene expression signature clearly distinguishes Burkitt lymphoma from DLBCL, a critical distinction in diagnosis.</description>
</item>
<item>
<title>Study outlines therapy for breast cancer with BRCA mutation</title>
<link>http://www.doctorslounge.com/oncology/articles/breast/brca_hormone/index.htm</link>
<description>Breast cancer with a certain genetic mutation can have breast-sparing surgery but should consider hormonal treatments.</description>
</item>
<item>
<title>St. Jude develops more affordable ALL follow-up test</title>
<link>http://www.doctorslounge.com/oncology/articles/leukemia/minimal_residual/index.htm</link>
<description>A new test could give hospitals with limited resources an affordable way to improve the outcome of ALL treatment.</description>
</item>
<item>
<title>Thalidomide plus Topotecan better for ovarian cancer</title>
<link>http://www.doctorslounge.com/oncology/articles/ovary/thalidomide_topotecan/index.htm</link>
<description>This trial is among the first to combine a biologic agent with a conventional chemotherapy agent for ovarian cancer.</description>
</item>
</channel>
</rss> 